{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:02:11Z","timestamp":1783004531369,"version":"3.54.5"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000835","name":"University of Bath","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Anti-TIF1\u03b3 is an important autoantibody in the diagnosis of cancer-associated dermatomyositis and the most common autoantibody in juvenile onset dermatomyositis. Its reliable detection is important to instigate further investigations into underlying malignancy in adults. We previously showed that commercial assays using line and dot blots do not reliably detect anti-TIF1\u03b3. We aimed to test a new commercial ELISA and compare with previously obtained protein immunoprecipitation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Radio-labelled immunoprecipitation had previously been used to determine the autoantibody status of patients with immune-mediated inflammatory myopathies and several healthy controls. ELISA was undertaken on healthy control and anti-TIF1\u03b3 sera and compared to previous immunoprecipitation data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 110 serum samples were analysed: 42 myositis patients with anti- TIF1\u03b3 and 68 autoantibody negative healthy control sera. Anti-TIF1\u03b3 was detected by ELISA in 41 out of 42 of the anti-TIF1\u03b3-positive samples by immunoprecipitation, and in none of the healthy controls, giving a sensitivity of 97.6% and specificity of 100%. The false negative rate was 2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ELISA is an affordable and time-efficient method which is accurate in detecting anti-TIF1\u03b3.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.804037","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T07:16:00Z","timestamp":1643354160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["A Commercial Anti-TIF1\u03b3 ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing"],"prefix":"10.3389","volume":"13","author":[{"given":"Ben","family":"Mulhearn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"McMorrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in Myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, Mutual Exclusivity and Clinical Associations of Myositis Autoantibodies in a Combined European Cohort of Idiopathic Inflammatory Myopathy Patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00992","article-title":"Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer","volume":"8","author":"Aussy","year":"2017","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key357","article-title":"The Temporal Relationship Between Cancer and Adult Onset Anti-Transcriptional Intermediary Factor 1 Antibody-Positive Dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 Antibody and Cancer-Associated Myositis: A Clinicohistopathologic Study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The Reliability of Immunoassays to Detect Autoantibodies in Patients With Myositis is Dependent on Autoantibody Specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatol (United Kingdom)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2018-214690","article-title":"Comparison of Autoantibody Specificities Tested by a Line Blot Assay and Immunoprecipitation-Based Algorithm in Patients With Idiopathic Inflammatory Myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164","article-title":"A Novel Autoantibody to a 155-Kd Protein Is Associated With Dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in Juvenile-Onset Myositis: Their Diagnostic Value and Associated Clinical Phenotype in a Large UK Cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.33403","article-title":"Myositis-Specific Anti-155\/140 Autoantibodies Target Transcription Intermediary Factor 1 Family Proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B13","article-title":"Distinct Dermatomyositis Populations are Detected With Different Autoantibody Assay Platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T07:16:03Z","timestamp":1643354163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2022.804037"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.804037","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"804037"}}